Bedrijfsoverzicht
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development of chimeric antigen receptor (CAR) cell therapies, specifically targeting light chain Amyloidosis and various immune-mediated diseases within the United States and Australian markets. The company operates within the Healthcare sector, specifically inside the Biotechnology industry, a field characterized by high research and development costs and significant regulatory hurdles before a product can reach commercial viability. Its current valuation reflects a market capitalization of $490.89M, while specific annual revenue and employee count figures are not disclosed in the available financial data. The substantial market cap relative to the lack of reported revenue and explicit employee numbers indicates that the company's valuation is driven primarily by the potential of its lead product, NXC-201, for relapsed/refractory AL Amyloidosis, rather than current cash flow generation or established market share.
Financiële gezondheid
The financial statements for Immix Biopharma, Inc. report a Net Income of $-29,438,612 and an EBITDA of $-29,710,668 for the trailing twelve months, while Revenue figures are not available in the current dataset. The significant negative gap between the reported Net Income and EBITDA suggests that the company incurs substantial non-operating expenses or interest costs that are not fully captured in the EBITDA metric, or conversely, that the EBITDA figure includes adjustments that result in a slightly less negative operating picture than the final net loss. The Free Cash Flow stands at $-13,612,449, indicating that the company is consuming cash to fund its operations and development pipeline rather than generating surplus liquidity from its core activities. This negative cash flow position implies a reliance on external capital sources, such as equity issuance or debt financing, to sustain operations until product commercialization occurs. The Gross Margin, Operating Margin, and Profit Margin are all reported at 0.0%, a figure typical for clinical-stage biotechnology firms where revenue is either non-existent or negligible compared to the massive costs of clinical trials and R&D. The company holds $100.41M in cash against a total debt obligation of only $1.07M, resulting in a Debt to Equity ratio of 1.14, which presents an unusual leverage profile for a cash-rich entity but reflects the specific accounting structure of its capitalization. The Current Ratio is exceptionally high at 10.01, signaling that the company possesses immense short-term liquidity and the ability to cover its current liabilities more than ten times over with its available current assets. Furthermore, the Return on Equity is -55.0% and the Return on Assets is -29.3%, metrics that mathematically reflect the aggressive spending required to advance clinical candidates rather than the profitability seen in mature pharmaceutical companies.
Waarderingsbeoordeling
The valuation metrics for Immix Biopharma, Inc. show a Trailing P/E Ratio of N/A due to the lack of positive earnings, while the Forward P/E is listed at -12.73, a negative figure that underscores the company's unprofitable status and the market's pricing based on future potential rather than current profitability. The Price to Book ratio is 5.23, indicating that the market values the company's equity at more than five times its book value, which typically suggests high expectations for future growth or a strong intangible asset base that is not fully reflected in the accounting book value. The Price to Sales ratio is N/A, and the EV/EBITDA stands at -13.16, providing alternative valuation perspectives that highlight the company's negative earnings power and the speculative nature of its current share price. The stock has exhibited significant volatility within the past year, trading between a 52-week low of $1.56 and a 52-week high of $11.61. The current share price sits at a level that requires specific calculation against the $1.60 minimum of the range, though the exact current price is not provided, the range demonstrates a wide trading band of approximately $10.05. The Beta is 0.21, a value significantly below 1.0, which indicates that the stock's price volatility is roughly 79% lower than the broader market, suggesting it is less sensitive to general market movements but carries idiosyncratic risks related to its specific drug development pipeline.
Growth & Income
The available financial data lists the Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, which is consistent with the company's pre-revenue or early-stage commercialization phase where historical growth rates cannot be calculated from prior periods. Because the company does not distribute a dividend, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning that instead of returning cash to shareholders, Immix Biopharma, Inc. retains all its earnings to reinvest into its research and development efforts. The absence of a dividend yield and the presence of negative net income confirm that the company's primary growth strategy involves funding clinical trials and regulatory submissions rather than paying income to investors. Consequently, the overall growth and income profile is defined entirely by the potential future success of its product portfolio, as there are no current income streams or historical growth trajectories to evaluate against market benchmarks.